Merck Serono Biosimilars Head Thierry Hulot On Minimizing Risks And Upfront Costs: An Interview With PharmAsia News
This article was originally published in PharmAsia News
Merck Serono is hopeful of capitalizing on the gaps existing in access for lifesaving oncology biosimilars
You may also be interested in...
Industry applauds a suggestion by a senior healthcare representative that the European Commission could re-examine the overarching guideline on biosimilars to promote global development, but growth ultimately will be determined by greater worldwide harmonization.
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.
In a bold move, little known Indian drug firm Lee Pharma has applied for a compulsory license for saxagliptin in India, contending that AstraZeneca sells the diabetes drug at an exorbitant local price and that it is not being made sufficiently available. Lee also says that the originator has not responded to calls to collaborate.